Captor Therapeutics Spolka Akcyjna (WSE:CTX)
Poland
· Delayed Price · Currency is PLN 83.20
-1.40 (-1.65%)
Mar 6, 2026, 3:44 PM CET
WSE:CTX Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 7.57 | 15.83 | 13.2 | 9.16 | 3.99 | - |
| Revenue Growth (YoY) | -60.89% | 19.88% | 44.15% | 129.75% | - | - |
| Cost of Revenue | 2.63 | 5.23 | 6.3 | 2.09 | 0.74 | - |
| Gross Profit | 4.95 | 10.6 | 6.9 | 7.07 | 3.25 | - |
| Selling, General & Admin | 11.71 | 11.46 | 16.14 | 24.07 | 30.68 | 9.89 |
| Research & Development | 45.12 | 43.9 | 70.89 | 44.16 | 23.12 | 23.57 |
| Other Operating Expenses | -9.83 | -5.79 | -7.11 | -22.79 | -17.71 | -21.24 |
| Operating Expenses | 47.01 | 49.56 | 79.92 | 45.44 | 36.09 | 12.22 |
| Operating Income | -42.06 | -38.97 | -73.02 | -38.36 | -32.84 | -12.22 |
| Interest Expense | -0.32 | -0.39 | -0.27 | -0.32 | -0.4 | -0.39 |
| Interest & Investment Income | 1.68 | 1.04 | 3.08 | 3.13 | - | - |
| Currency Exchange Gain (Loss) | -0.01 | -0.07 | -0.27 | -0.08 | -0.06 | -0.09 |
| Other Non Operating Income (Expenses) | -0 | -0.05 | -0.05 | -0.26 | -0.41 | - |
| EBT Excluding Unusual Items | -40.71 | -38.43 | -70.53 | -35.89 | -33.7 | -12.69 |
| Asset Writedown | - | - | - | - | 1.13 | - |
| Pretax Income | -40.71 | -38.43 | -70.53 | -35.89 | -32.57 | -12.69 |
| Income Tax Expense | - | - | 0.06 | - | - | - |
| Net Income | -40.71 | -38.43 | -70.58 | -35.89 | -32.57 | -12.69 |
| Net Income to Common | -40.71 | -38.43 | -70.58 | -35.89 | -32.57 | -12.69 |
| Shares Outstanding (Basic) | 5 | 5 | 5 | 4 | 4 | 4 |
| Shares Outstanding (Diluted) | 5 | 5 | 5 | 4 | 4 | 4 |
| Shares Change (YoY) | 6.24% | 0.30% | 11.46% | 0.97% | 14.99% | - |
| EPS (Basic) | -7.68 | -8.25 | -15.19 | -8.61 | -7.89 | -3.54 |
| EPS (Diluted) | -7.69 | -8.25 | -15.19 | -8.61 | -7.89 | -3.54 |
| Free Cash Flow | -7.8 | -32.3 | -55.21 | -23.84 | -33.59 | -0.81 |
| Free Cash Flow Per Share | -1.47 | -6.93 | -11.88 | -5.72 | -8.14 | -0.23 |
| Gross Margin | 65.32% | 66.95% | 52.28% | 77.21% | 81.41% | - |
| Operating Margin | -555.61% | -246.24% | -553.11% | -418.91% | -823.88% | - |
| Profit Margin | -537.79% | -242.82% | -534.69% | -391.94% | -817.16% | - |
| Free Cash Flow Margin | -103.04% | -204.12% | -418.22% | -260.32% | -842.60% | - |
| EBITDA | -37.4 | -33.91 | -67.58 | -31.27 | -25.49 | -5.61 |
| EBITDA Margin | - | -214.27% | - | - | - | - |
| D&A For EBITDA | 4.66 | 5.06 | 5.44 | 7.09 | 7.36 | 6.6 |
| EBIT | -42.06 | -38.97 | -73.02 | -38.36 | -32.84 | -12.22 |
| EBIT Margin | - | -246.24% | - | - | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.